Bio-Rad Exhibits Complete Infectious Disease Testing Portfolio at ECCMID 2022

Increasing antibiotic resistance among microbial populations is one of the major public health concerns. To fight antibiotic resistance spread, AST Systems must allow biologists to accurately diagnose specific resistance phenotypes, according to official CLSI & EUCAST guidelines. At this year’s ECCMID, Bio-Rad exhibited its complete and up-to-date range of antimicrobial susceptibility testing products, from AST reagents to the ADAGIO system, dispenser, and susceptibility media. The ADAGIO Antimicrobial Susceptibility Testing System is an automated imaging device that reads and interprets antibiotic disks and MIC strips. The Bio-Rad automatic disk recognition feature improves the reading process for reliability and confidence in your result interpretation. The ADAGIO system is designed to fit into the microbiology laboratory organization and to provide high-quality AST results. Patient data results are securely stored in the ADAGIO software allowing accurate epidemiology studies to be built based on customized statistical analysis. Bio-Rad also demonstrated its comprehensive line of antimicrobial susceptibility disks for semi-quantitative in vitro susceptibility testing of previously isolated pure cultures of microorganisms.

Additionally, Bio-Rad highlighted its full range of serological immunoassay reagents, testing systems, and expertise for meeting mycology testing challenges. Among its mycology testing solutions, Bio-Rad demonstrated its serological assays for detecting antigens of Candida, Aspergillus, and Cryptococcus neoformans as well as antibodies using standardized antigens of Candida and Aspergillus. The company also demonstrated how its EIA microplate-based assays for mycology testing can be performed using manual, semi-automated, or fully-automated instrument systems including its EVOLIS Systems. The EVOLIS and the EVOLIS Twin Plus systems assure the highest level of laboratory safety with positive identification of samples and reagents and a unique triple pipetting verification technology (capacitive, barometric & colorimetric detection).

Bio-Rad also presented its Geenius Confirmatory Solution to help labs confirm and differentiate individual antibodies to HIV-1 and HIV-2 and to confirm the presence of anti-HCV antibodies. The company also demonstrated its high-performance screening assays for the detection of HIV, HCV, HBV, and syphilis along with comprehensive systems that ensure reliable and safe results for blood donor screening.

Related Links:
Bio-Rad Laboratories